An analysis of United States data reveals a broad shift away from overtreatment of low-risk prostate cancer. The analysis ...
A crowd of South African men ran through the streets of Johannesburg in purple swim briefs to raise awareness about prostate ...
AstraZeneca has punted a pair of early-phase prostate cancer progra | AstraZeneca has punted a pair of early-phase prostate ...
From 2014 through 2022, the rate of prostate cancers being diagnosed in the US increased by about 3% per year. About 1 in 8 men will be diagnosed with prostate cancer during their lifetime. But each ...
The approval makes the PARP inhibitor available earlier in the line of treatment for some patients with metastatic disease.
Pfizer’s Talzenna is now the first PARP inhibitor approved by the FDA to treat men with metastatic hormone-sensitive prostate ...
About TALZENNA® (talazoparib) TALZENNA is an oral inhibitor of poly ADP-ribose polymerase (PARP), which plays a role in DNA damage repair. Preclinical studies have demonstrated that TALZENNA blocks ...
The FDA has expanded its approval of talazoparib in combination with enzalutamide to include men with metastatic androgen ...
Over the last 15 years, low-risk prostate cancer has become less common at diagnosis and is increasingly managed through active surveillance, according to research published in Ca ...
HealthDay News — Low-risk prostate cancer (PC) has become less common at diagnosis since 2010, and low-risk patients are increasingly avoiding treatment, according to a study published online Oct. 26 ...
An analysis of United States data reveals a broad shift away from overtreatment of low-risk prostate cancer. The analysis ...
Talzenna-Xtandi secures an FDA label expansion as the cancer treatment paradigm shifts towards the use of mutation-specific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results